CSU | Jotup

Allakos Provides Business Update and Reports First Quarter 2024 Financial Results

Retrieved on:

Donnerstag, Mai 9, 2024

AAAAI, American Academy, Inflammation, Investment, Pharmacokinetics, Research, SAD, Lirentelimab, Patient, Allergy, Antibody, Annual general meeting, PD, CSU, SAN, Pharmaceutical industry

SAN CARLOS, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the first quarter ended March 31, 2024.

Key Points:

SAN CARLOS, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the first quarter ended March 31, 2024.
Allakos’ financial outlook, restructuring activities and estimated cash runway as reported by the Company in January 2024 remain unchanged.
Allakos reported a net loss of $71.1 million in the first quarter of 2024 compared to $42.4 million in the first quarter of 2023.
Net loss per basic and diluted share was $0.81 for the first quarter of 2024 compared to $0.49 in the first quarter of 2023.

Largest Veterinary Emergency Hospital in Tel Aviv Acquires Sensus Healthcare’s SRT-100™ to Provide Gentler Radiotherapy to Treat Tumors in Dogs and Cats

Retrieved on:

Donnerstag, Mai 9, 2024

Knowledge, Sale, Fort Collins, Colorado, Radiation, Animal, Colorado State University, Beit Berl College, Turtle, SRT, Cat, Veterinary medicine, Patient, Emergency, Neoplasm, Dog, Bird, CSU, Horse, Medical imaging

BOCA RATON, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces the sale of an SRT-100 system to Chavat Da’at, the Veterinary Specialist Referral Center Knowledge Farm at Beit Verl College in Tel Aviv, to provide a gentler radiotherapy option to treat tumors in dogs and cats. This is the first commercial sale of the SRT-100 for veterinary use outside the U.S.

Key Points:

Soon thereafter, an Emergency and Critical Care Center was established, which operates 24 hours a day.
Knowledge Farm is the largest private Veterinary Specialty Referral Center in Israel with more than 20 board-certified specialists and emergency physicians, and more than 30 qualified veterinary technicians and support staff.
“Whether for treating small animals like cats, dogs, turtles and birds, or large ones like horses, our technology is a valuable addition to leading veterinary practices worldwide.
These leaders are exploring and expanding the veterinary indications for radiotherapy, while making treatments increasingly available and affordable to many more pet owners,” he added.

Jasper Therapeutics to Present at Upcoming Investor Conferences in May

Retrieved on:

Dienstag, Mai 7, 2024

News, CD117, Therapy, EDT, Conference, CSU, Event, Perfume

REDWOOD CITY, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced that its management will present at the following upcoming investor conferences in May:

Key Points:

REDWOOD CITY, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced that its management will present at the following upcoming investor conferences in May:
Presentation Date: Tuesday, May 14 at 2:45 p.m. EDT
Presentation Date: Wednesday, May 15 at 3:35 p.m. EDT
A live webcast of the RBC Conference fireside chat will be available on the Events & News – Presentations page of Jasper's Investor Relations website.
An archived replay of the fireside chat will be available on Jasper's website for 30 days following the live broadcast.

Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on:

Montag, Mai 6, 2024

HAMPTON, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the first quarter ended March 31, 2024 and provided a corporate update.

Key Points:

Celldex is currently planning two Phase 3 studies of barzolvolimab in CSU, which are expected to initiate this summer.
Revenues: Total revenue was $0.2 million in the first quarter of 2024, compared to $1.0 million for the comparable period in 2023.
G&A Expenses: General and administrative (G&A) expenses were $9.1 million in the first quarter of 2024, compared to $6.6 million for the comparable period in 2023.
Financial Guidance: Celldex believes that the cash, cash equivalents and marketable securities at March 31, 2024 are sufficient to meet estimated working capital requirements and fund current planned operations through 2027.

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Webcast and Conference Call Today at 4:30 p.m. ET

Retrieved on:

Montag, Mai 6, 2024

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today reported financial results for its fiscal second quarter ended March 31, 2024.

Key Points:

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today reported financial results for its fiscal second quarter ended March 31, 2024.
For financial reporting purposes, the transaction was treated as debt, with the upfront purchase payment of $200.0 million recorded as a liability.
Interest expense from the royalty sale was $2.6 million for the three months ended March 31, 2024.
JMP Securities Life Sciences Conference, May 14, 2024
Enanta plans to issue its fiscal third quarter financial results press release on August 5, 2024.

Record Breaking Atlantic Hurricane Season Looms - Are People Ready?

Retrieved on:

Montag, Mai 6, 2024

The Harris Poll, Generac, Weather, Pet, Risk, Safety, Electricity, Tropical cyclone, Family, Food, CSU

WAUKESHA, Wis., May 6, 2024 /PRNewswire/ -- Generac Power Systems (NYSE: GNRC), a leading global designer, manufacturer and provider of energy technology solutions and other power products, is urging homeowners across the East and Gulf Coasts to prepare now for power outages following predictions for this year to have an active hurricane season.

Key Points:

The 2024 Atlantic hurricane season threatens to be the strongest in recent years, according to Colorado State University's annual Atlantic hurricane season forecast .
Twenty-three named storms are expected, eleven of which could become hurricanes, and five with the potential to reach major hurricane strength.
"This year's Atlantic hurricane season promises to be a dangerous one, and residents living in hurricane-prone areas need to take this season seriously," said Kyle Raabe, president of Consumer Power for Generac.
Generac offers an annual Hurricane Preparedness Guide to help homeowners prepare for the storm season.

Triple-I Stresses Preparedness for ‘Very Active’ 2024 Atlantic Hurricane Season

Retrieved on:

Freitag, Mai 3, 2024

A typical Atlantic hurricane season has 14 named storms, seven hurricanes and three major hurricanes.

Key Points:

A typical Atlantic hurricane season has 14 named storms, seven hurricanes and three major hurricanes.
With more Americans living in harm’s way than ever before, it is critical for everyone residing in a hurricane-prone community to make preparedness a priority for the upcoming season,” Kevelighan added.
National Hurricane Preparedness Week , spearheaded by the National Oceanic and Atmospheric Administration (NOAA), starts on Sunday, May 5, and continues through Saturday, May 11.
The Triple-I’s four key hurricane preparedness tips for the 2024 season include:
Review Your Insurance Coverage.

Newark Native Mohamed Kamara Selected as 158th Draft Pick by the Miami Dolphins

Retrieved on:

Mittwoch, Mai 1, 2024

NFL, Miami Dolphins, Colorado State University, Central High School, Master, Bachelor, Athlete, National Football League Draft, Human development, CSU, Nursing

His athleticism continued post-graduation when he committed to Colorado State University (CSU) as a 3-star recruit.

Key Points:

His athleticism continued post-graduation when he committed to Colorado State University (CSU) as a 3-star recruit.
At CSU, he exceeded expectations, earning the title of Mountain West Defensive Player of the Year.
On Saturday, April 27, 2024, his journey reached new heights when he was selected by the Miami Dolphins as the 158th pick in the NFL Draft, a testament to his skill, determination, and passion for the game.
"We are ecstatic to witness Mohamed Kamara's ascent in his football career," exclaimed Principal Terri Mitchell.

Colorado State University Global’s Teaching and Learning Programs Impact K-12 Education in Colorado

Retrieved on:

Donnerstag, April 18, 2024

Online, CO, Vice-principal, Certification, News, School, Colorado State University–Global Campus, Student, History, CSU, K-12, MSTL, Nursing

The programs’ educational and hands-on learning advancement opportunities empower educators across the state and beyond, to make a difference in their personal lives, classrooms, and communities.

Key Points:

The programs’ educational and hands-on learning advancement opportunities empower educators across the state and beyond, to make a difference in their personal lives, classrooms, and communities.
That’s why we’ve created flexible programs that allow educators to advance their careers without having to step away from the classroom.
What’s more, its PL program is the only 100% online program of its kind authorized by the state of Colorado.
Further, graduates can transfer those credits into a Master’s Degree in Teaching and Learning, reducing their time and costs to degree completion.

Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria

Retrieved on:

Mittwoch, April 17, 2024

Patient, Safety, Skin, Survival, CFT, CTT, Disease, Week, KIT, Temperature, Therapy, CSU, Pharmaceutical industry

HAMPTON, N.J., April 17, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that patient enrollment has been completed in the Company’s Phase 2 clinical study of barzolvolimab for the treatment of the two most common forms of chronic inducible urticaria (CIndU)—cold urticaria (ColdU) and symptomatic dermographism (SD).

Key Points:

HAMPTON, N.J., April 17, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that patient enrollment has been completed in the Company’s Phase 2 clinical study of barzolvolimab for the treatment of the two most common forms of chronic inducible urticaria (CIndU)—cold urticaria (ColdU) and symptomatic dermographism (SD).
Mast cell activation is known to be a critical driver in ColdU and SD.
In February 2024, the Company presented positive 12 week primary endpoint results from its ongoing Phase 2 study of barzolvolimab in the most common form of chronic urticaria—chronic spontaneous urticaria (CSU).
"We are very grateful to all the investigators and patients who supported this trial," said Anthony Marucci, President and Chief Executive Officer of Celldex Therapeutics.